1259519-61-3

Basic information

• Product Name: N-(3-ethynylphenyl)-7-methoxy-6-(2-methoxyethoxy)quinazolin-4-amine
• Synonyms: N-(3-ethynylphenyl)-7-methoxy-6-(2-methoxyethoxy)quinazolin-4-amine
• CAS NO: 1259519-61-3
• Molecular Weight: 349.389
• Mol File: 1259519-61-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(3-ethynylphenyl)-7-methoxy-6-(2-methoxyethoxy)quinazolin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-ethynylphenyl)-7-methoxy-6-(2-methoxyethoxy)quinazolin-4-amine(1259519-61-3)
• EPA Substance Registry System: N-(3-ethynylphenyl)-7-methoxy-6-(2-methoxyethoxy)quinazolin-4-amine(1259519-61-3)

Safety Data

• Hazardous Substances Data: 1259519-61-3(Hazardous Substances Data)

Upstream product

• 905306-05-0 4-[(3-acetylenephenyl)amino]-7-methoxyquinazolin-6-ol 
• 16427-44-4 2-methoxyethyl methanesulfonate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 54060-30-9 3-acetylenephenylamine 
• 116168-89-9 4-methoxy-3-(2-methoxyethoxy)benzaldehyde 

Downstream Products

• 1259519-21-5 N-(3-ethynyl-d-phenyl)-7-methoxy-6-(2-methoxyethoxy)quinazolin-4-amine 

Relevant articles and documents

Synthesis and biological assay of erlotinib analogues and BSA-conjugated erlotinib analogue

A series of erlotinib analogues that have structural modification at 6,7-alkoxyl positions is efficiently synthesized. The in vitro anti-tumor activity of synthesized compounds is studied in two non-small cell lung cancer (NSCLC) cell lines (A549 and H1975). Among the synthesized compounds, the iodo compound 6 (ETN-6) exhibits higher anti-cancer activity compared to erlotinib. An efficient method is developed for the conjugation of erlotinib analogue-4, alcohol compound, with protein, bovine serum albumin (BSA), via succinic acid linker. The in vitro anti-tumor activity of the protein attached erlotinib analogue, 8 (ETN-4-Suc-BSA), showed stronger inhibitory activity in both A549 and H1975 NSCLC cell lines.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF

The present invention is directed to novel quinolines and quniazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R1 to R11 and X are defined herein.